Valsartan

• Hypertension
• Heart Failure
• Post-Myocardial Infarction
• Cardiovascular Protection

Valsartan (brand name Diovan) is an angiotensin II receptor blocker (ARB) used to treat hypertension, heart failure due to coronary artery disease, and to reduce mortality after myocardial infarction in patients with left ventricular dysfunction. It is one of the most widely prescribed agents in cardiovascular medicine because it provides robust blood pressure and end-organ benefit without the cough that limits ACE inhibitors for many patients, and because it carries strong outcomes data across all three of its major indications.

Mechanism of Action

Valsartan selectively and reversibly antagonizes the angiotensin II type 1 (AT1) receptor. Blocking this receptor prevents the vasoconstriction, sodium retention, aldosterone secretion, sympathetic activation, and pro-fibrotic cardiac and vascular signaling that angiotensin II would otherwise produce. Unlike ACE inhibitors such as lisinopril, ramipril, and enalapril, ARBs do not interfere with the bradykinin pathway, which is why ARBs cause cough and angioedema only rarely — bradykinin accumulation is the principal driver of the dry cough that affects 10 to 20 percent of patients on ACE inhibitors.

Valsartan does not require hepatic activation, has a half-life of around six hours, and is excreted predominantly unchanged in bile, with a small renal component. The duration of antihypertensive effect extends well beyond the plasma half-life because of slow dissociation from the receptor, supporting once-daily dosing for hypertension. Within the ARB class, valsartan is pharmacologically similar to losartan, olmesartan, telmisartan, candesartan, and irbesartan; valsartan and candesartan have the strongest randomized trial evidence in heart failure with reduced ejection fraction.

Clinical Use

For uncomplicated essential hypertension, ARBs and ACE inhibitors are first-line in non-Black adults under 60 with or without diabetes, often combined with a thiazide diuretic such as hydrochlorothiazide or a calcium channel blocker like amlodipine. For Black patients without diabetes, calcium channel blockers and thiazides are usually started first, with ARBs added if needed. The understanding blood pressure numbers and controlling high blood pressure articles provide the patient-facing context.

For patients with reduced ejection fraction heart failure, the combination sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor) has supplanted plain ARB or ACE inhibitor monotherapy in most cases, based on the PARADIGM-HF trial showing a 20 percent reduction in cardiovascular death or heart failure hospitalization compared with enalapril. Plain valsartan remains relevant for patients who cannot tolerate or afford the combination, or who have had angioedema with an ACE inhibitor and need the ARB component without the neprilysin inhibitor.

After myocardial infarction with left ventricular dysfunction, valsartan was shown in the VALIANT trial to be non-inferior to captopril for mortality. ARBs are also used for renal protection in chronic kidney disease with proteinuria, particularly in patients with diabetes, where they slow progression of nephropathy independent of blood pressure lowering. Patients with prior stroke benefit from blood pressure control, and ARBs are reasonable agents in this setting. The American Heart Association's high blood pressure resources summarize the broader treatment framework.

How to Take It

Valsartan is taken once or twice daily depending on indication, with or without food at the same time each day. For hypertension, common starting doses are 80 to 160 mg once daily, titrated to 320 mg as needed; for heart failure, the regimen is 40 mg twice daily titrated to a target of 160 mg twice daily as tolerated over several weeks. Most of the antihypertensive effect appears within two weeks, with peak effect by four weeks.

Patients should be cautioned that abruptly stopping the drug can cause rebound blood pressure elevation. Potassium-rich salt substitutes (potassium chloride) should be used cautiously because valsartan can raise serum potassium; over-the-counter NSAIDs such as ibuprofen and naproxen blunt blood pressure control and increase the risk of acute kidney injury, particularly in patients on combined ARB and diuretic therapy. Hot weather, vomiting, diarrhea, or fever can precipitate symptomatic hypotension by combining with the drug's vasodilator effect — patients should know to hydrate, watch for dizziness, and call if they cannot keep fluids down. The MedlinePlus valsartan page is a useful patient handout.

Monitoring and Follow-Up

Baseline serum creatinine, potassium, and a urinalysis are obtained before initiation. Renal function and potassium are rechecked one to two weeks after starting or after any dose increase, particularly in older adults, patients with chronic kidney disease, or those on diuretics or potassium-sparing agents. A modest rise in creatinine of up to 30 percent is expected and is not a reason to stop the drug — it reflects expected hemodynamic effect on glomerular filtration; larger increases or a rise in potassium above 5.5 mEq/L warrants reassessment.

Blood pressure is reviewed at every visit, and home blood pressure monitoring is encouraged for both diagnostic confirmation and titration. The understanding blood work lab panels article describes basic metabolic panel components in patient-friendly terms. Periodic urine albumin-to-creatinine ratio is helpful in patients being treated for kidney protection, particularly those with diabetes. The FDA prescribing information is available through accessdata.fda.gov.

Special Populations

ARBs carry a boxed warning for fetal toxicity — they cause oligohydramnios, neonatal renal failure, and skull hypoplasia in the second and third trimesters, and any pregnancy on an ARB should be reviewed urgently with the prescriber and ideally the obstetric team. Combination with an ACE inhibitor, or with the renin inhibitor aliskiren in patients with diabetes, is contraindicated due to higher rates of hyperkalemia, syncope, and renal dysfunction without offsetting clinical benefit.

In patients on lithium, ARBs raise lithium levels and require closer monitoring. In severe heart failure, intravascular volume depletion, or high-dose diuretic therapy, the first dose can produce profound hypotension, so initiation is often done at a lower dose with subsequent titration. No dose adjustment is required for mild-to-moderate hepatic impairment or for renal impairment in adults, although bilateral renal artery stenosis is a relative contraindication because of risk of acute kidney injury. Older adults generally start at lower doses with attention to orthostatic blood pressure changes.

Lifestyle and Supportive Care

Medication is one component of blood pressure and heart failure management; lifestyle measures are equally important and often allow lower medication doses. The DASH dietary pattern — rich in vegetables, fruits, whole grains, lean proteins, and low-fat dairy, with limited saturated fat and added sugar — lowers systolic blood pressure by 8 to 14 mmHg in motivated patients. Sodium restriction to less than 2,300 mg daily, and ideally closer to 1,500 mg in patients with established hypertension or heart failure, adds further benefit. Reading labels matters because most dietary sodium comes from packaged and restaurant foods rather than the saltshaker.

Weight loss of 1 mmHg of systolic blood pressure for every kilogram lost is a typical response in overweight or obese patients. Regular aerobic exercise — at least 150 minutes per week of moderate intensity — lowers blood pressure independently of weight change. Resistance training adds modest benefit. Limiting alcohol to no more than one drink per day for women and two for men, and quitting smoking, both produce measurable improvement.

For patients with heart failure, daily weight monitoring (with a sudden 2 to 3 pound gain prompting a call) is one of the most powerful self-management tools. Sodium and fluid restriction, adherence to all heart failure medications, vaccination against influenza and pneumococcus, and a structured exercise program (cardiac rehabilitation where indicated) reduce hospitalization risk. Stress management, adequate sleep, and treatment of obstructive sleep apnea where present further support cardiovascular health. Home blood pressure monitoring with a validated upper-arm device, recorded over time, provides much better information than occasional office readings and engages patients in their own care.

When to Contact Your Doctor

Swelling of the lips, tongue, or throat (rare angioedema) is a medical emergency requiring immediate care. Significant lightheadedness, fainting, decreased urination, or symptoms of high potassium (muscle weakness, palpitations, irregular heartbeat) should be reported promptly. Pregnancy or planned pregnancy should prompt an immediate medication review. Persistent dry cough, while less common with ARBs than ACE inhibitors, can still occur and is worth mentioning at follow-up.

If you have questions about valsartan or your blood pressure or heart failure treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.